Viewing Study NCT00092625



Ignite Creation Date: 2024-05-05 @ 11:36 AM
Last Modification Date: 2024-10-26 @ 9:10 AM
Study NCT ID: NCT00092625
Status: COMPLETED
Last Update Posted: 2022-02-15
First Post: 2004-09-23

Brief Title: Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease 0653-803
Sponsor: Organon and Co
Organization: Organon and Co

Study Overview

Official Title: A Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate Efficacy Safety and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease
Status: COMPLETED
Status Verified Date: 2022-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patients current approved cholesterol lowering medication
Detailed Description: The duration of treatment is 10 weeks

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2004_041 None None None